🟢 Relay Therapeutics is trading 4.03% up on supportive read-through from Pfizer’s Phase 2 trial

Relay Therapeutics is trading 4.03% higher at $19.60 on October 28, 2026, as investors respond to Pfizer’s Phase 2 FOURLIGHT-1 atirmociclib data, which Jefferies viewed as supportive read-through for Relay’s zovegalisib combination. - Jefferies cited first-line potential; a cross-trial comparison showed grade 3-or-higher treatment-related events of 40% for Relay’s triplet versus 88.3% for Roche’s regimen. - A second consecutive daily gain followed October 27’s 3.97% rise; volume was light. The broader biotech rally was sector context, not the clearest company-specific explanation.